BioSpace News Archive

Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”), is pleased to report its financial results for the three months ended March 31, 2020 (“Q1 2020”).

GO2 Foundation for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, Ph.D., to the role of chief scientific officer.

The global market for body protection equipment is anticipated to witness a healthy growth in the forthcoming years, as reported by Transparency Market Research.

The demand within the global stem cell banking market is growing on account of advancements in the field of regenerative medicine.

The global animal genetics market is likely to rise at a healthy growth rate over the assessment timeframe.

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock.

Developed with Mayo Clinic, the algorithm helps identify low ejection fraction - a sign of heart failure and a significant comorbidity for COVID-19 patients OAKLAND, Calif.--( BUSINESS WIRE )-- Eko , a digital health company building AI-powered screening and telehealth solutions to fight cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has issued the company an Emergency Use Authorization (EUA) for its novel

QurAlis Corporation, a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the raise of a $42 million Series A financing, bringing the total funds raised to $50.5 million.

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a virtual Key Opinion Leader (“KOL”) meeting to discuss the chronic cough landscape on Wednesday, May 27, 2020 at 9:00 a.m. EDT. The event will featur

Sustained enzyme activity up to 22 months and consistent trends demonstrated across multiple other measures in first patient in Fabry disease Phase 2 clinical trial Data from first patient treated using plato TM gene therapy platform in Fabry disease trial show: 43-percent reduction in toxic metabolite plasma lyso-Gb3 one month post-treatment Significantly higher leukocyte and plasma enzyme activity three months post-treatmen